Format

Send to

Choose Destination
Hum Pathol. 2017 Mar;61:68-77. doi: 10.1016/j.humpath.2016.11.001. Epub 2016 Nov 15.

Role of miR-139 as a surrogate marker for tumor aggression in breast cancer.

Author information

1
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160.
2
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160. Electronic address: otawfik@kumc.edu.

Abstract

MicroRNAs are non-protein coding molecules that play a key role in oncogenesis, tumor progression, and metastasis in many types of malignancies including breast cancer. In the current study, we studied the expression of microRNA-139-5p (miR-139) in invasive ductal carcinoma (IDC) of the breast and correlated its expression with tumor grade, molecular subtype, hormonal status, human epidermal growth factor receptor 2 status, proliferation index, tumor size, lymph node status, patient's age, and overall survival in 74 IDC cases. In addition, we compared and correlated miR-139 expression in 18 paired serum and tissue samples from patients with IDC to assess its value as a serum marker. Our data showed that miR-139 was down-regulated in all tumor tissue samples compared with control. More pronounced down-regulation was seen in tumors that were higher grade, estrogen receptor negative, progesterone receptor negative, more proliferative, or larger in size (P < .05). Although not statistically significant, lower miR-139 level was frequently associated with human epidermal growth factor receptor 2 overexpression. In addition, significantly lower miR-139 tissue level was seen in patients who were deceased (P = .027), although older age (>50 years) and positive local nodal disease did not adversely affect miR-139 expression. In contrast, serum miR-139 profile of the patients appeared similar to that of normal control. In conclusion, our study demonstrated that down-regulation of miR-139 was associated with aggressive tumor behavior and disease progression in breast cancer. miR-139 may serve as a risk assessment biomarker in tailoring treatment options.

KEYWORDS:

Breast cancer; Invasive ductal carcinoma; Micro RNA; MicroRNA-139; Oncogenesis; Tumor progression

PMID:
27864119
DOI:
10.1016/j.humpath.2016.11.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center